2. Search Result
Search Result
Results for "

carcinoid

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

5

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1368
    Fenclonine
    Maximum Cited Publications
    19 Publications Verification

    4-Chloro-DL-phenylalanine; PCPA; CP-10188

    		 Tryptophan Hydroxylase Neurological Disease Cancer
    Fenclonine is a selective and irreversible tryptophan hydroxylase inhibitor, which is a rate-limiting enzyme in the biosynthesis of serotonin. Fenclonine can be used in carcinoid syndrome research .
    Fenclonine
  • HY-W772850
    Fenclonine hydrochloride
    Maximum Cited Publications
    19 Publications Verification

    4-Chloro-DL-phenylalanine hydrochloride; PCPA hydrochloride; CP-10188 hydrochloride

    		 Tryptophan Hydroxylase Neurological Disease Cancer
    Fenclonine hydrochloride is a selective and irreversible tryptophan hydroxylase inhibitor, which is a rate-limiting enzyme in the biosynthesis of serotonin. Fenclonine hydrochloride can be used in carcinoid syndrome research .
    Fenclonine hydrochloride
  • HY-P1959
    Lanreotide

    BIM 23014

    		 Somatostatin Receptor Endocrinology Cancer
    Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome .
    Lanreotide
  • HY-P1959A
    Lanreotide acetate

    BIM 23014 acetate

    		 Somatostatin Receptor Endocrinology Cancer
    Lanreotide (BIM 23014) acetate is a somatostatin analogue with antineoplastic activity. Lanreotide acetate can be used for the research of carcinoid syndrome .
    Lanreotide acetate
  • HY-106033
    Edotreotide
    1 Publications Verification

    DOTATOC; SDZ-SMT 487; SMT 487

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    Edotreotide is a ligand that selectively targets SSTR2 and can competitively bind to the receptor. Edotreotide mediates the targeted delivery, while modificated with radionuclides (such as 90Y, 177Lu, and 68Ga) to SSTR-positive tumors and induces tumor cell apoptosis by releasing β rays. Edotreotide has strong tumor targeting and precise killing activity. Edotreotide is used in the synthesis of radionuclide-drug conjugates (RDCs) and is widely used in the field of neuroendocrine tumors (such as metastatic carcinoids, lung and thymus NETs) .
    Edotreotide
  • HY-15472
    PRX-08066

    		5-HT Receptor p38 MAPK TGF-β Receptor FGFR Apoptosis Caspase Cardiovascular Disease Neurological Disease Cancer
    PRX-08066 is a selective and orally active 5-hydroxytryptamine receptor 2B (5-HT2BR) antagonist with a Ki of 3.4 nM. PRX-08066 inhibits the MAPK pathway, 5-HT release and fibrotic factor (TGFβ1, CTGF and FGF2) expression. PRX-08066 inhibits the proliferation of KRJ-I cells and induces apoptosis (caspase-3 activation). PRX-08066 inhibits pulmonary vascular remodeling. PRX-08066 can be used of pulmonary Arterial Hypertension (PAH) and neuroendocrine tumor (NET) .
    PRX-08066
  • HY-B1368R
    Fenclonine (Standard)

    		Tryptophan Hydroxylase Neurological Disease Cancer
    Fenclonine (Standard) is the analytical standard of Fenclonine. This product is intended for research and analytical applications. Fenclonine is a selective and irreversible tryptophan hydroxylase inhibitor, which is a rate-limiting enzyme in the biosynthesis of serotonin. Fenclonine can be used in carcinoid syndrome research .
    Fenclonine (Standard)
  • HY-P1959B
    Lanreotide diTFA

    BIM 23014 diTFA

    		 Somatostatin Receptor Endocrinology Cancer
    Lanreotide (BIM 23014) diTFA is a somatostatin analogue with antineoplastic activity. Lanreotide diTFA can be used for the research of carcinoid syndrome .
    Lanreotide diTFA
  • HY-125314
    AG-041R

    		Cholecystokinin Receptor Endocrinology Cancer
    AG-041R is a potent and selective CCK2 Receptor/Gastrin antagonist. AG-041R inhibits gastrin-evoked secretion of pancreastatin with an IC50 of 2.2 nM. AG-041R inhibits cell growth of Mastomys ECL carcinoid tumor cells .
    AG-041R
  • HY-15472A
    PRX-08066 maleate

    		5-HT Receptor p38 MAPK TGF-β Receptor FGFR Apoptosis Caspase Cardiovascular Disease Neurological Disease Cancer
    PRX-08066 maleate is a selective and orally active 5-hydroxytryptamine receptor 2B (5-HT2BR) antagonist with a Ki of 3.4 nM. PRX-08066 maleate inhibits the MAPK pathway, 5-HT release and fibrotic factor (TGFβ1, CTGF and FGF2) expression. PRX-08066 maleate inhibits the proliferation of KRJ-I cells and induces apoptosis (caspase-3 activation). PRX-08066 maleate inhibits pulmonary vascular remodeling. PRX-08066 maleate can be used of pulmonary Arterial Hypertension (PAH) and neuroendocrine tumor (NET) .
    PRX-08066 maleate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: